12:00 AM
 | 
Jun 17, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GSK2618960: Phase I halted

GlaxoSmithKline halted a 3-part, U.K. Phase I trial evaluating GSK2618960, a compound developed in part from research in a January 2010 Nature Medicine paper determined by GSK to contain "wrongly characterized" data. The first and second single-blind parts were designed to evaluate single and repeat ascending-doses of GSK2618960 in 48 healthy volunteers, and the third open-label part was designed to evaluate...

Read the full 285 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >